New Treatment Paradigms Monograph
|New Treatment Paradigms in Second-line Therapy for Pancreatic Cancer|
Tanios Bekaii-Saab, MD, FACP
|Release Date: June 01, 2016|
Expiration Date: June 01, 2017
|This activity will describe treatment options in the second-line setting for patients with advanced (metastatic) pancreatic cancer. Dr. Tanios Bekaii-Saab explains new treatment paradigms in second-line therapy given the approval of nanoliposomal irinotecan, including therapeutic selection based on prior therapy and toxicities of currently available agents.|
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Merrimack Pharmaceuticals, Inc.
|View Only, CE ExpiredView Only, No Credit|